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ABSTRACT
Background
Blinding is a cornerstone of therapeutic evaluation because lack of blinding can bias
treatment effect estimates. An inventory of the blinding methods would help trialists conduct
high-quality clinical trials and readers appraise the quality of results of published trials. We
aimed to systematically classify and describe methods to establish and maintain blinding of
patients and health care providers and methods to obtain blinding of outcome assessors in
randomized controlled trials of pharmacologic treatments.
Methods and Findings
We undertook a systematic review of all reports of randomized controlled trials assessing
pharmacologic treatments with blinding published in 2004 in high impact-factor journals from
Medline and the Cochrane Methodology Register. We used a standardized data collection form
to extract data. The blinding methods were classified according to whether they primarily (1)
established blinding of patients or health care providers, (2) maintained the blinding of patients
or health care providers, and (3) obtained blinding of assessors of the main outcomes. We
identified 819 articles, with 472 (58%) describing the method of blinding. Methods to establish
blinding of patients and/or health care providers concerned mainly treatments provided in
identical form, specific methods to mask some characteristics of the treatments (e.g., added
flavor or opaque coverage), or use of double dummy procedures or simulation of an injection.
Methods to avoid unblinding of patients and/or health care providers involved use of active
placebo, centralized assessment of side effects, patients informed only in part about the
potential side effects of each treatment, centralized adapted dosage, or provision of sham
results of complementary investigations. The methods reported for blinding outcome assessors
mainly relied on a centralized assessment of complementary investigations, clinical
examination (i.e., use of video, audiotape, or photography), or adjudication of clinical events.
Conclusions
This review classifies blinding methods and provides a detailed description of methods that
could help trialists overcome some barriers to blinding in clinical trials and readers interpret the
quality of pharmalogic trials.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
Randomized controlled trials (RCTs) are widely recognized
as the criterion standard for unbiased assessment of the effect
of different pharmacologic treatments. Blinding is used in
combination with randomization to limit the occurrence of
conscious and unconscious bias in the conduct of clinical
trials (performance bias) and interpretation of outcomes
(ascertainment bias). Blinding is not well understood. For
example, it has been demonstrated that the terms single and
double blind frequently used by researchers and widely
accepted by readers as a key marker of validity of an RCT
lack consistency in use and interpretation [1–3]. In clinical
trials, blinding in RCTs refers to keeping study participants,
health care providers, and those assessing outcomes unaware
of the assigned intervention. Empirical evidence suggests that
lack of blinding involves inﬂated treatment effect estimates
[2,4–6]. In fact, blinded patients may report symptoms
differently from unblinded patients or have different thresh-
olds for leaving a trial or seeking additional treatment outside
a trial. Similarly, lack of blinding of health care providers can
result in systematic differences in care provided apart from
the intervention being evaluated (performance bias). Fur-
thermore, lack of blinding of outcome assessors can result in
systematic differences in outcome assessment (ascertainment
bias) [7,8]. Blinding is particularly important when outcome
measures involve some subjectivity, such as assessment of pain
or cause of death. Blinding is probably less important for
more objective outcomes such as death, because the risk of
ascertainment bias is limited. An example of ascertainment
bias was seen in a multiple sclerosis trial in which assessment
by unblinded neurologists demonstrated an apparent treat-
ment beneﬁt, whereas that by blinded neurologists did not [9].
Blinding of patients and health care providers can be
difﬁcult to establish at the start of a trial and to maintain
during a trial. For example, unblinding may occur during the
trial for patients and health care providers because of speciﬁc
side effects or speciﬁc requirements such as dosage mod-
iﬁcation [10,11]. Furthermore, obtaining blinded outcome
assessment in clinical trials is difﬁcult, for example, if patients
are not blinded and could reveal their treatment to the
outcome assessor. Whether these problems are overcome
depend in part on the quality and creativity of the blinding
methods.
To our knowledge, a detailed description of blinding
methods has never been published. Thus, we aimed to
describe and classify methods used for blinding in RCTs
assessing pharmacologic treatment. This classiﬁcation should
help in the dissemination of these methods for trialists who
perform RCTs and also the assessment of the quality of
results of clinical trials for readers.
Methods
We systematically summarized and categorized the method
of blinding patients, health care providers, and outcome
assessors in RCTs of pharmacologic treatment published in
2004 in high impact-factor journals.
Search Strategy and Selection of Reports
We identiﬁed reports of all RCTs published in 2004 in high
impact-factor journals (three highest impact factors for each
subject category of the Journal Citation Reports 2003 [12],
such as cardiac and cardiovascular system, respiratory system
or rheumatology, and ten of the highest-impact general
medical journals) and indexed in Medline by searching
PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db¼PubMed) using the terms ‘‘double-blind method’’
[MESH term] OR ‘‘single-blind method’’ [MESH term] limited
to RCTs. This search strategy might have missed some articles
describing a blinded method; however, our aim was not to be
exhaustive but to provide a description of blinding methods
and to propose a useful classiﬁcation.
One of us (IB) assessed retrieved reports by screening the
titles and abstracts to identify the relevant studies. We
included reports only if the study design was identiﬁed as
an RCT assessing pharmacologic treatments and published as
a full-text article. We excluded nonrandomized trials,
pharmacokinetic studies, follow-up trials, diagnostic assess-
ment, pathophysiologic studies, and ancillary studies from an
RCT for subgroup analysis, cost-effectiveness trials, meta-
analyses, and trials assessing nonpharmacologic treatments.
After obtaining the full text, we selected reports only if they
reported that there was blinding of at least one of the
following: patients, health care providers, or outcome
assessors.
We furthermore searched for reports on blinding indexed
in the Cochrane Methodology Register (http://www.cochrane.
org/access_data/cmr/accessDB_cmr.asp) using the term
‘‘blind.’’ We included reports if, in the title or abstract,
authors reported the use of a speciﬁc method of blinding or a
speciﬁc placebo. We gathered additional relevant trials by
searching references of relevant selected reports or those
known by members of our team or experts in this ﬁeld.
Data Extraction
The research team compiled a standardized data collection
form. Before data extraction, as a planned calibration
exercise, four members of the team (IB, CE, LG, and AD)
independently evaluated a separate set of ten reports. At a
meeting, the group reviewed evaluations and resolved any
disagreements by consensus. We randomly allocated the
selected articles to each reviewer, who independently
completed the data extraction for one-quarter of the articles
selected. Reviewers assessed the title, abstract, methods, and
results sections.
We obtained data on the description of the experimental
treatment (oral drug, intramuscular, intravenous, intra-
articular treatment, or other) and the control treatment
(placebo, active control treatment, or usual care). Reviewers
also identiﬁed and classiﬁed the primary outcome according
to speciﬁc criteria used previously [13] as (1) a patient-
reported outcome, whereby the patient is the outcome
assessor (e.g., pain, disability, quality of life); (2) physician-
driven data that suppose a contact between patients and
outcome assessors (e.g., range of motion); (3) complementary
investigations that do not suppose a contact between patients
and outcome assessors (e.g., international normalization
ratios within the target range, angiographic restenosis); or
(4) a clinical event determined by the interaction between
patients and care providers (e.g., death, myocardial infarc-
tion, stroke, dialysis, or blood transfusion). Reviewers
extracted the reported blinding status for patients, health
care providers, and outcome assessors and checked whether
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Methods of Blindingthe methods of blinding were described and how. For this
purpose, reviewers checked for the reporting of a method to
establish blinding for patients and/or health care providers—
that is, methods to provide indistinguishable treatments in
each arm such as use of matching placebo, bottle covered
with an opaque bag, or use of a double dummy. Reviewers
also checked for the reporting of a procedure to avoid
unblinding of patients and/or care providers because of side
effects or speciﬁc requirements such as dosage modiﬁcations.
Finally, we recorded the description of speciﬁc methods of
blinded outcome assessments such as patients being informed
not to tell the outcome assessors what treatment they
received or centralized assessment of complementary inves-
tigations.
Classification
We used a simple system to classify the blinding methods
according to (1) who was blinded (patient, health care
providers, or outcome assessors) and (2) a distinction between
establishing and maintaining blinding. Thus, we classiﬁed
blinding methods according to whether they primarily (1)
established blinding of patients or health care providers
(through the mode of administration and the physical
characteristics of the treatments), (2) maintained the blinding
of patients or health care provider (through the risk of
unblinding by speciﬁc adverse effects or speciﬁc require-
ments such as dosage modiﬁcations), or (3) obtained the
blinding of assessors (through the category of main outcome,
i.e., patient-reported outcome, physician-driven data, com-
plementary investigations, and clinical events).
Statistical Analysis
We describe descriptive statistics for categorical variables
with frequencies and percentages. All data analyses involved
use of the SAS system for Windows, Release 9.1 (SAS Institute,
Cary, North Carolina, United States).
Results
Articles Selected
We retrieved 1,040 articles by electronic search and
excluded 211 reports on the basis of the title and abstract
and 42 articles after obtaining the full text. Finally, we
selected 32 articles by personal searching and use of
references. Thus, we assessed a total of 819 articles (Figure 1).
Characteristics of the Included Articles
Table 1 details the characteristics of the included articles.
The selected articles assessed mainly treatments in the ﬁeld of
cardiology (123/819 [15%]), endocrinology, nutrition and
dietetics (88/819 [11%]); musculoskeletal system (80/819
Figure 1. Study Screening Process
DOI: 10.1371/journal.pmed.0030425.g001
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Methods of Blinding[10%]); anesthesiology, pain, and critical care (78/819 [9%]);
and the respiratory system (63/819 [8%]). The experimental
treatments concerned mainly oral drugs and topical treat-
ments (508/819 [62%]) and injections such as intravenous,
intramuscular, or intra-articular treatment (178/819 [22%]). A
total of 613 reports (75%) described a placebo control
treatment in at least one arm of the trial, and 196 (32% of the
placebo-controlled trials) the content of the placebo (e.g.,
sugar, saline solution).
The main outcomes reported were patient-reported out-
comes (114/819 [14%]), physician-driven data (203/819 [25%]),
complementary investigations (207/819 [25%]), clinical events
(157/819 [19%]), and multiple outcomes (119/819 [15%]). The
main outcome was unclear in 18 articles (2%).
A total of 576 reports (71%) clearly reported blinding for
patients, 276 (34%) health care providers, and 405 (50%)
outcome assessors. Success of blinding was described in 35
reports (5%).
Method of Blinding
More than half of the reports (472 [58%]) described the
method of blinding, but 236 (29%) gave no detail and 111
(13%) some data on blinding (i.e., reporting that treatments
were similar or the use of double dummies with no
description of the method). The methods of blinding
identiﬁed varied in complexity.
Methods to Establish Blinding of Patients or Health Care
Providers
A total of 336 reports (41%) described methods to establish
blinding of patients or health care providers (Figure 2). The
authors reported use of a centralized preparation of similar
capsules, tablets, or embedded treatments in hard gelatin
capsules (193/336 [57%]), similar syringes (37/336 [11%]), or
similar bottles (38/336 [11%]). Use of a double dummy
procedure was described in 79 articles (23%). Other methods
consisted of a sham intervention performed by an unblinded
health care provider who was not actively involved in the
care of patients and had no other contact with patients or
other caregivers and outcome assessors (17/336 [5%]). To
mask the speciﬁc taste of the active treatments, in ten articles
researchers used a speciﬁc ﬂavor such as peppermint or
sugar to coat treatments. For treatments administered by
care providers, authors reported use of a centralized
preparation of opaque coverage to adequately conceal
intravenous treatments with different appearances (14/336
[4%]). Appendix 1 in Protocol S1 gives examples of these
methods.
Table 1. Characteristics of the Articles Selected for Assessing Blinding in RCTs
Category Variable Reported in Study Total (n ¼ 819) Percentage of Total
Medical area Cardiac and cardiovascular system 123 15
Endocrinology and metabolism/nutrition 88 11
Musculoskeletal system 80 10
Anesthesiology/pain/critical care 78 9
Respiratory system 63 8
Neurology 56 7
Psychiatry/psychology 49 6
Infectious diseases 48 6
Pediatrics 45 5
Obstetric gynecology 38 5
Gastroenterology and hepatology 32 4
Other 119 15
Experimental treatment Oral drugs or topical treatments 508 62
Injections (intravenous, intramuscular, intra-articular treatments) 178 22
Other mode of administration or several arms 126 15
Complex treatment (different component) 7 1
Control treatment Placebo 424 52
Active control treatment 187 23
Placebo and active control treatment 188 23
Other 20 2
Blinding status Patients only 196 24
Health care providers only 1 0.1
Outcome assessors only 59 7
Patients and health care providers 40 5
Patients and outcome assessors 111 14
Health care providers and outcome assessors 6 1
Patients, health care providers, and outcome assessors 229 28
Main outcomes Patient-reported outcome 114 14
Physician-driven data 203 25
Paraclinical examination 207 25
Clinical event 157 19
Multiple outcomes 119 15
Unclear 18 2
Other 1 0.1
DOI: 10.1371/journal.pmed.0030425.t001
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Methods of BlindingMethods to Avoid Unblinding of Patients or Health Care
Providers
Very few studies overall (28/819 [3%]) reported methods to
avoid unblinding. Figure 3 presents these methods, which
concern only treatments necessitating dosage adaptation or
those with frequent and/or speciﬁc side effects. These
methods relied on use of a centralized adapted dosage or
provision of sham results of complementary investigations
for treatments necessitating dosage adaptation.
Methods to avoid unblinding because of side effects relied
mainly on centralized assessment of side effects, partial
information to patients about side effects, use of active
placebo or systematic prevention of adverse effects in both
arms. Appendix 2 in Protocol S1 gives examples of methods
to avoid unblinding of patients or health care providers.
Methods of Blinded Assessment
These methods depend on the main outcomes and are
particularly useful when blinding cannot be established and
maintained by the methods described previously. A total of
112 articles (14%) described these methods, which relied
mainly on a centralized assessment of the main outcome
(Figure 4). Appendix 3 in Protocol S1 gives examples of these
methods. Blinding of outcome assessors will presumably be
achieved if neither patients nor those involved in the trial
have any means to discover which arm a patient is in, for
example because the placebo and active drugs are indistin-
guishable and allocation is via a central randomization
service. Speciﬁc measures to blind outcome assessors may
thus be required mainly when the nature of the trial is such
that complete blinding during the earlier stages is not
feasible. However, in this sample, 96 reports (86%) over the
Figure 2. Methods to Establish Blinding in RCTs
Methods of blinding of patients or health care providers (i.e., to provide indistinguishable treatments) were determined for published reports of RCTs of
pharmacologic treatment.
DOI: 10.1371/journal.pmed.0030425.g002
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Methods of Blinding112 reports in which speciﬁc measures to blind the outcome
assessor were reported concern trials in which patients were
reported as blinded or in which double blinding or triple
blinding was reported. These results suppose that although
blinding was performed at an earlier stage, trialists never-
theless decided to perform a speciﬁc method of blinding the
outcome assessor.
Discussion
This study assessed the reporting of the methods of
blinding in RCTs of pharmacologic treatment and provides
a description and classiﬁcation of methods of blinding
patients, health care providers, and outcome assessors based
on a large cohort of RCTs. We identiﬁed 819 reports with
about 60% describing the method of blinding. Our classi-
ﬁcation identiﬁed three main methods of blinding: (1)
methods to provide identical treatments in both arm, (2)
methods to avoid unblinding during the trial, and (3) methods
of blinded outcome assessment.
Although blinding is essential to avoid bias, the reporting
of blinding is generally quite poor [5] and reviews of trials
that test the success of blinding methods indicate that a high
proportion of trials are unblinded [14,15]. Lack of reporting
of blinding [5,14–16] is probably linked in part to the lack of
awareness of existing methods of blinding. To improve the
performance and reporting of the method of blinding, we
established an inventory of blinding methods of patients,
health care providers, and main outcome assessors and
classiﬁed them mainly on the basis of what seemed reasonable
after having read through the various methods. Although
other ways of classifying could be considered, we decided to
focus on the mode of administration of the treatments, the
risk of unblinding, and the primary outcomes, as these are
Figure 3. Methods to Avoid Unblinding
Methods to avoid unblinding of patients or health care providers (i.e., to avoid unblinding during the trials because of specific side effects or specific
requirements such as dosage modification) were determined in published reports of RCTs of pharmacologic treatment.
DOI: 10.1371/journal.pmed.0030425.g003
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Methods of Blindingmore practical and logical criteria for researchers when
planning trials.
Our classiﬁcation emphasizes that blinding outcome
assessors depends mainly on the primary outcome. In most
situations, blinding outcome assessors should therefore be
possible with a centralized assessment of complementary
investigation, physician-mediated data, and clinical events
(Figure 4). For example, for the assessment of gastroscopy,
endoscopic procedures could be completely recorded using a
VHS recorder and evaluated under blinded conditions [17].
In a trial comparing the use of two analgesic treatments
during a vaccination procedure of children, the procedure
was videotaped. A mirror was mounted on the wall behind the
examining table so that the observer could ﬁlm the infant’s
reaction both face on and from the mirror image. A trained
observer, who was unaware of the treatment assignment,
scored the pain of vaccination from the videotapes using the
Modiﬁed Behavioral Pain Scale [18]. These methods are
probably more successful than the method of informing
patients not to tell outcome assessors the treatment they
received. In fact, a study comparing conservative treatment
(splinting) with surgery in the treatment of carpal tunnel
syndrome involved an attempt to blind the outcome assessor
by encouraging the patients not to reveal their treatment and
by masking the surgical scar. Despite these efforts, the
assessor correctly guessed the treatment performed [19].
Finally, for patient-reported outcomes for which the patient
is the outcome assessor, if no methods can overcome the
difﬁculties in establishing and maintaining blinding, no
methods should be used so as to avoid ascertainment bias
by a blinded outcome assessment.
This systematic review also highlights some creative
methods of blinding that are frequently used in speciﬁc
areas and could overcome some barriers to blinding. For
example, in a trial comparing ximelagatran and warfarin for
the prevention of venous thromboembolism, to avoid
unblinding an anticoagulation management center relayed
real or sham values to health care providers [20]. In a trial
comparing the efﬁcacy of inﬂiximab versus placebo for
psoriatic arthritis, to offer active medication to patients
randomized to receive placebo, patients with less than 10%
improvement from baseline entered early escape and
received inﬂiximab at weeks 16, 18, and 22. To maintain
blinding, patients randomized to receive inﬂiximab who had
less than 10% improvement received additional placebo
infusions at weeks 16, 18, and 22 [21]. Some reports have
proposed use of active placebo. Active placebos are designed
and used to mimic some of the side effects of the intervention
to further secure blinding [22–26]. For example, in a trial to
investigate the immunologic response of three doses of cat
Figure 4. Methods of Blinded Outcome Assessment in Published Reports of RCTs Assessing Pharmacologic Treatment
DOI: 10.1371/journal.pmed.0030425.g004
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Methods of Blindinghair compared to placebo, researchers added caramelized
sugar and histamine to the placebo and to the two lowest
doses of cat extract to simulate the local reaction of the most
concentrated extract [27].
However, some of these methods might be debatable from
an ethical point of view. For example, use of active placebo is
ethically debatable, and researchers should consider the
balance between the expected harm linked to the placebo
and the expected beneﬁt of administering an active placebo
[26]. Further, some ethics committees might reject a study
involving blinding patients to some hypotheses such as not
informing them about side effects of medication. However,
this method might be acceptable if patients are informed
about all the possible side effects but not informed of speciﬁc
side effects of the treatment administered.
The classiﬁcation and dissemination of these methods to
researchers could overcome some barriers of blinding.
Consequently, this classiﬁcation (Figures 2–4) and the de-
tailed examples of reporting (Protocol S1) should be helpful
to researchers in planning trials as well as to readers and
reviewers in appraising the feasibility of blinding in published
reports of clinical trials.
Finally, our results also concludes that only 58% of the
reports provided some details of the methods used to blind
patients, health care providers, and outcome assessors. These
results are consistent with those of Ferguson et al. [16], who
showed that matching of the characteristics of placebo to the
intervention was reported in 53% of trials. These results
might be explained in part by the insufﬁcient coverage of
blinding in the Consolidated Standards for Reporting Trials
(CONSORT) statements. In fact, empirical evidence has
demonstrated that lack of blinding and allocation conceal-
ment could bias the results [4,6,28]. To take into account
these issues, three items of the CONSORT statements are
dedicated to the description of the randomization procedure,
whereas only one item is dedicated to the blinding issue [29].
The CONSORT statements mainly focus on reporting who is
blinded [2] and less on the reporting of details on the method
of blinding, whereas this information is essential to appraise
the success of blinding. In fact, some evidence suggests that
although participants are reported as blinded, the success of
blinding might be questionable [11]. For instance, in a study
assessing zinc treatment for the common cold, the blinding
procedure failed, because the taste and aftertaste of zinc was
distinctive [11,30]. Nevertheless tools used to assess the
quality of trials included in meta-analyses and systematic
reviews mainly focus on the reporting of the blinding status
for each participant [31–33], and rarely on the description of
the blinding methods and the adequacy of the blinding
method [34]. Therefore, we must strengthen the reporting
guidelines related to blinding issues, emphasizing adequate
reporting of the method of blinding.
In this study, we assessed reports of RCTs published in high
impact-factor journals from 2004. Consequently, we focused
only on a speciﬁc panel of RCTs and on the reporting of these
trials, not the trials themselves [29,35]. For example, we could
not provide data on the methods of blinding data collectors,
because these data were poorly reported, and we were unable
to consistently identify data collectors in the selected articles.
In addition, if the method of blinding was detailed in another
article, we did not check for the description of the method.
Thus, some methods of blinding might have been missed.
However, the high number of contemporary trials included
implies that we described a substantial number of blinding
methods and also highlighted creative methods of blinding.
Furthermore, these results are evolving, and readers are
invited to inform us of other methods of blinding not
captured in this survey. Finally, we did not focus on other key
trial participants, such as data analysts. However, there is no
reason that data analysts could not be blinded, and therefore
the identiﬁcation and dissemination of speciﬁc methods of
blinding data analysts is probably not necessary.
In conclusion, this study highlights two important issues.
First, our detailed description and classiﬁcation of several
ways to establish and maintain blinding helps ensure a
blinded outcome assessment in RCTs. These methods should
be disseminated to researchers to overcome some of the
barriers to blinding in clinical trials. Second, we conﬁrmed
the insufﬁcient reporting of the methods of blinding and the
need to increase the requirement related to blinding issues in
the CONSORT statements.
Supporting Information
Protocol S1. Appendices
Three appendices are provided. Appendix 1 reports examples of the
methods used to establish blinding in the selected published reports
of randomized controlled trials. Appendix 2 focuses on the examples
of the methods to avoid unblinding in randomized controlled trials.
Appendix 3 provides examples of the methods to blind outcome
assessors.
Found at DOI: 10.1371/journal.pmed.0030425.sd001 (140 KB DOC).
Acknowledgments
Author contributions. IB, DLS, AH, and PR designed the study. IB
analyzed the data. IB, CE, LG, LG, AD, DLS, AH, and PR contributed
to writing the paper. IB, CE, LG, and AD collected data or did
experiments for the study.
References
1. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Guyatt GH (2001) Physician
interpretations and textbook deﬁnitions of blinding terminology in
randomized controlled trials. JAMA 285: 2000–2003.
2. Schulz KF, Chalmers I, Altman DG (2002) The landscape and lexicon of
blinding in randomized trials. Ann Intern Med 136: 254–259.
3. Schulz KF, Grimes DA (2002) Blinding in randomised trials: Hiding who got
what. Lancet. 359: 696–700.
4. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of
bias. Dimensions of methodological quality associated with estimates of
treatment effects in controlled trials. JAMA 273: 408–412.
5. Schulz KF, Grimes DA, Altman DG, Hayes RJ (1996) Blinding and exclusions
after allocation in randomised controlled trials: Survey of published parallel
group trials in obstetrics and gynaecology. BMJ 312: 742–744.
6. Gluud LL (2006) Bias in clinical intervention research. Am J Epidemiol 163:
493–501.
7. Hrobjartsson A, Gotzsche PC (2001) Is the placebo powerless? An analysis
of clinical trials comparing placebo with no treatment. N Engl J Med 344:
1594–1602.
8. Hrobjartsson A (2002) What are the main methodological problems in the
estimation of placebo effects? J Clin Epidemiol 55: 430–435.
9. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, et al.
(1994) The impact of blinding on the results of a randomized, placebo-
controlled multiple sclerosis clinical trial. Neurology 44: 16–20.
10. Desbiens N (2002) In randomized controlled trials, should subjects in both
placebo and drug groups be expected to guess that they are taking drug
50% of the time? Med Hypotheses 59: 227–232.
11. Desbiens NA (2000) Lessons learned from attempts to establish the blind in
placebo-controlled trials of zinc for the common cold. Ann Intern Med 133:
302–303.
12. Thomson Scientiﬁc (2003) Journal citation reports. Available: http://
isiwebofknowledge.com. Accessed 20 September 2006.
13. Boutron I, Tubach F, Giraudeau B, Ravaud P (2004) Blinding was judged
more difﬁcult to achieve and maintain in non-pharmacological than
pharmacological trials. J Clin Epidemiol 57: 543–550.
14. Hrobjartsson A, Forfang E, Haahr M, Als-Nielsen B, Stig B (2004) Testing
PLoS Medicine | www.plosmedicine.org October 2006 | Volume 3 | Issue 10 | e425 1938
Methods of Blindingthe success of blinding in randomised clinical trials [abstract]. 12th
Cochrane Colloquium: Bridging the Gaps; 2004 October 2–6; Ottawa,
Ontario, Canada. pp. 138–139.
15. Boutron I, Estellat C, Ravaud P (2005) A review of blinding in randomized
controlled trials found results inconsistent and questionable. J Clin
Epidemiol 58: 1220–1226.
16. Fergusson D, Glass KC, Waring D, Shapiro S (2004) Turning a blind eye:
The success of blinding reported in a random sample of randomised,
placebo controlled trials. BMJ 328: 432.
17. Fiorucci S, Mencarelli A, Meneguzzi A, Lechi A, Renga B, et al. (2004) Co-
administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents
platelet and monocyte activation and protects against gastric damage
induced by aspirin in humans. J Am Coll Cardiol 44: 635–641.
18. O’Brien L, Taddio A, Ipp M, Goldbach M, Koren G (2004) Topical 4%
amethocaine gel reduces the pain of subcutaneous measles-mumps-rubella
vaccination. Pediatrics 114: e720–e724.
19. Gerritsen AA, de Vet HC, Scholten RJ, Bertelsmann FW, de Krom MC, et al.
(2002) Splinting vs surgery in the treatment of carpal tunnel syndrome: A
randomized controlled trial. JAMA 288: 1245–1251.
20. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, et al.
(2003) Comparison of ximelagatran with warfarin for the prevention of
venous thromboembolism after total knee replacement. N Engl J Med 349:
1703–1712.
21. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, et al. (2005)
Inﬂiximab improves signs and symptoms of psoriatic arthritis: Results of
the IMPACT 2 trial. Ann Rheum Dis 52: 1227–1236.
22. Flaten MA, Simonsen T, Zahlsen K, Aamo T, Sager G, et al. (2004) Stimulant
and relaxant drugs combined with stimulant and relaxant information: A
study of active placebo. Psychopharmacology (Berl) 176: 426–434.
23. Wu CL, Tella P, Staats PS, Vaslav R, Kazim DA, et al. (2002) Analgesic effects
of intravenous lidocaine and morphine on postamputation pain: A
randomized double-blind, active placebo-controlled, crossover trial.
Anesthesiology 96: 841–848.
24. Dellemijn PL, Vanneste JA (1997) Randomised double-blind active-
placebo-controlled crossover trial of intravenous fentanyl in neuropathic
pain. Lancet 349: 753–758.
25. Shaw RW (1978) Randomized controlled trial of Syn-Ergel and an active
placebo in the treatment of heartburn of pregnancy. J Int Med Res 6:
147–151.
26. Edward SJ, Stevens AJ, Braunholtz DA, Lilford RJ, Swift T (2005) The ethics
of placebo-controlled trials: A comparison of inert and active placebo
controls. World J Surg 29: 610–614.
27. Nanda A, O’Connor M, Anand M, Dreskin S C, Zhang L, et al. (2004) Dose
dependence and time course of the immunologic response to admin-
istration of standardized cat allergen extract. J Allergy Clin Immunol 114:
1339–1344.
28. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of
reports of randomised trials affect estimates of intervention efﬁcacy
reported in meta-analyses? Lancet 352: 609–613.
29. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, et al. (2001) The
revised CONSORT statement for reporting randomized trials: Explanation
and elaboration. Ann Intern Med 134: 663–694.
30. Prasad AS, Fitzgerald JT, Bao B, Beck FW, Chandrasekar PH (2000)
Duration of symptoms and plasma cytokine levels in patients with the
common cold treated with zinc acetate. A randomized, double-blind,
placebo-controlled trial. Ann Intern Med 133: 245–252.
31. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996)
Assessing the quality of reports of randomized clinical trials: Is blinding
necessary? Control Clin Trials 17: 1–12.
32. Verhagen AP, de Vet HC, de Bie RA, Boers M, van den Brandt PA (2001)
The art of quality assessment of RCTs included in systematic reviews. J Clin
Epidemiol 54: 651–654.
33. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, et al. (1998) The
Delphi list: A criteria list for quality assessment of randomized clinical
trials for conducting systematic reviews developed by Delphi consensus. J
Clin Epidemiol 51: 1235–1241.
34. Boutron I, Moher D, Tugwell P, Giraudeau B, Poiraudeau S, et al. (2005) A
checklist to evaluate a report of a nonpharmacological trial (CLEAR NPT)
was developed using consensus. J Clin Epidemiol 58: 1233–1240.
35. Pildal J, Chan AW, Hrobjartsson A, Forfang E, Altman DG, et al. (2005)
Comparison of descriptions of allocation concealment in trial protocols
and the published reports: Cohort study. BMJ 330: 1049.
Editors’ Summary
Background. In evidence-based medicine, good-quality randomized
controlled trials are generally considered to be the most reliable source
of information about the effects of different treatments, such as drugs. In
a randomized trial, patients are assigned to receive one treatment or
another by the play of chance. This technique helps makes sure that the
two groups of patients receiving the different treatments are equivalent
at the start of the trial. Proper randomization also prevents doctors from
controlling or affecting which treatment patients get, which could distort
the results. An additional tool that is also used to make trials more
precise is ‘‘blinding.’’ Blinding involves taking steps to prevent patients,
doctors, or other people involved in the trial (e.g., those people
recording measurements) from finding out which patients got what
treatment. Properly done, blinding should make sure the results of a trial
are more accurate. This is because in an unblinded study, participants
may respond better if they know they have received a promising new
treatment (or worse if they only got placebo or an old drug); doctors may
‘‘want’’ a particular treatment to do better in the trial, and unthinking
bias could creep into their measurements or actions; the same applies for
practitioners and researchers who record patients’ outcomes in the trial.
However, blinding is not a simple, single step; the people carrying out
the trial often have to set up a variety of different procedures that
depend on the type of trial that is being done.
Why Was This Study Done? The researchers here wanted to thoroughly
examine different methods that have been used to achieve blinding in
randomized trials of drug treatments, and to describe and classify them.
They hoped that a better understanding of the different blinding
methods would help people doing trials to design better trials in the
future, and also help readers to interpret the quality of trials that had
been done.
What Did the Researchers Do and Find? This group of researchers
conducted what is called a ‘‘systematic review.’’ They systematically
searched the published medical literature to find all randomized, blinded
drug trials published in 2004 in a number of different ‘‘high-impact’’
journals (journals whose articles are often mentioned in other articles).
Then, the researchers classified information from the published trial
reports. The researchers ended up with 819 trial reports, and nearly 60%
of them described how blinding was done. Their classification of blinding
was divided up into three main areas. First, they detailed methods used
to hide which drugs are given to particular patients, such as preparing
identically appearing treatments; using strong flavors to mask taste;
matching the colors of pills; using saline injections and so on. Second,
they described a number of methods that could be used to reduce the
risk of unblinding (of doctors or patients), such as using an ‘‘active
placebo’’ (a sugar pill that mimics some of the expected side effects of
the drug treatment). Finally, they defined methods for blinded
measurement of outcomes (such as using a central committee to collect
data).
What Do These Findings Mean? The researchers’ classification will help
people to work out how different techniques can be used to achieve,
and keep, blinding in a trial. This will assist others to understand whether
any particular trial was likely to have been blinded properly, and
therefore work out whether the results are reliable. The researchers also
suggest that, generally, blinding methods are not described in enough
detail in published scientific papers, and recommend that guidelines for
describing results of randomized trials be improved.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030425.
  James Lind Library has been created to help patients and researchers
understand fair tests of treatments in health care by illustrating how
fair tests have developed over the centuries
  ClinicalTrials.gov, a trial registry created by the US National Institutes
of Health, has an introduction to understanding clinical trials
  National Electronic Library for Health introduction to controlled clinical
trials
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